Healios KK
TSE:4593

Watchlist Manager
Healios KK Logo
Healios KK
TSE:4593
Watchlist
Price: 170 JPY -0.58% Market Closed
Market Cap: 15.3B JPY
Have any thoughts about
Healios KK?
Write Note

Operating Margin
Healios KK

-556.7%
Current
-6 866%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-556.7%
=
Operating Profit
-3.1B
/
Revenue
549m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
JP
Healios KK
TSE:4593
15.3B JPY
-557%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
310.2B USD
28%
US
Amgen Inc
NASDAQ:AMGN
142B USD
19%
US
Gilead Sciences Inc
NASDAQ:GILD
115B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
101.6B USD
40%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
134.4B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.5B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36B EUR
-22%
Country JP
Market Cap 15.3B JPY
Operating Margin
-557%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 310.2B USD
Operating Margin
28%
Country US
Market Cap 142B USD
Operating Margin
19%
Country US
Market Cap 115B USD
Operating Margin
38%
Country US
Market Cap 101.6B USD
Operating Margin
40%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 134.4B AUD
Operating Margin
26%
Country US
Market Cap 78.5B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 36B EUR
Operating Margin
-22%
No Stocks Found

Healios KK
Glance View

Market Cap
15.3B JPY
Industry
Biotechnology

Healios KK engages in the research, development, and sale of cellular and regenerative medicine. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 116 full-time employees. The company went IPO on 2015-06-16. is a Japan-based company mainly engaged in research and development of pharmaceutical products. The firm has compound pharmaceutical products line and induced pluripotent stem cell (iPSC) regenerative medicine product line. The compound pharmaceutical product line contains HLM0021, HLM0022 and HLM0023. The products are ophthalmological surgery adjuvants, mainly contain brilliant blue G-250 (BBG250) which help capsule temporarily safely stained to protect the inner limiting membranes and lens during surgery of vitreous and cataract. The iPSC regenerative medicine product line contains HLCR011 and HLCR012. The products are in the preclinical testing and preparation for trial in Japan, which are candidate of regenerative medicine products. The products are iPS cell derived retinal pigment epithelium (RPE) cell suspension and sheet developed in Japan, United States and Europe.

Intrinsic Value
142.38 JPY
Overvaluation 16%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-556.7%
=
Operating Profit
-3.1B
/
Revenue
549m
What is the Operating Margin of Healios KK?

Based on Healios KK's most recent financial statements, the company has Operating Margin of -556.7%.